Droperidol Dosage

This dosage information may not include all the information needed to use Droperidol safely and effectively. See additional information for Droperidol.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Nausea/Vomiting

To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures:

Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely.

Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.

Usual Adult Dose for Nausea/Vomiting - Postoperative

To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures:

Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely.

Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.

Usual Pediatric Dose for Nausea/Vomiting

To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures:

Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely.

Children 2 to 12 years:
Postoperative nausea and vomiting (PONV):
Prophylaxis, if high risk for PONV: 0.01 to 0.015 mg/kg/dose IM or IV given near the end of surgery Maximum dose: 1.25 mg
Administer additional doses after at least 6 hours with caution and only if potential benefit outweighs risks.
(Previous reports suggested a higher dose of 0.075 mg/kg as effective; however, due to side effects associated with the higher doses, doses greater than 0.05 mg/kg are considered excessive and no longer recommended.)

Treatment (not first line): IV:
Manufacturer recommendations: 0.1 mg/kg/dose. Administer additional doses with extreme caution and only if potential benefit outweighs risks.

Alternate dosing: Doses as low as 0.01 to 0.015 mg/kg/dose (up to 0.03 mg/kg) may be effective for breakthrough nausea and vomiting
Maximum initial dose: 0.1 mg/kg
Administer additional doses after at least 6 hours with caution and only if potential benefit outweighs risks.

Usual Pediatric Dose for Nausea/Vomiting - Postoperative

To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures:

Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely.

Children 2 to 12 years:
Postoperative nausea and vomiting (PONV):
Prophylaxis, if high risk for PONV: 0.01 to 0.015 mg/kg/dose IM or IV given near the end of surgery Maximum dose: 1.25 mg
Administer additional doses after at least 6 hours with caution and only if potential benefit outweighs risks.
(Previous reports suggested a higher dose of 0.075 mg/kg as effective; however, due to side effects associated with the higher doses, doses greater than 0.05 mg/kg are considered excessive and no longer recommended.)

Treatment (not first line): IV:
Manufacturer recommendations: 0.1 mg/kg/dose. Administer additional doses with extreme caution and only if potential benefit outweighs risks.

Alternate dosing: Doses as low as 0.01 to 0.015 mg/kg/dose (up to 0.03 mg/kg) may be effective for breakthrough nausea and vomiting
Maximum initial dose: 0.1 mg/kg
Administer additional doses after at least 6 hours with caution and only if potential benefit outweighs risks.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

The initial dose of droperidol should be appropriately reduced in elderly, debilitated, and other poor risk patients. The effect of the initial dose should be considered in determining incremental doses.

Precautions

QT prolongation and/or torsades de pointes have been reported in patients receiving droperidol at doses which were at or below recommended doses. Some of the cases have been reported in patients with no known risk factors for QT prolongation and some have been fatal. All patients should undergo a 12-lead ECG prior to administration of droperidol to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If a prolonged QT interval is present, droperidol should not be administered. For patients in whom the potential benefit of droperidol is felt to outweigh the risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for two to three hours after completing treatment to monitor for arrhythmias. Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, cardiac hypertrophy, hypokalemia, or hypomagnesemia). Other risk factors may include age over 65 years or alcohol abuse.

Droperidol is contraindicated for use in the treatment of patients with known or suspected QT prolongation, including patients with congenital long QT syndrome. Droperidol is not recommended for any use other than for the treatment of perioperative nausea and vomiting in patients for whom other therapies are ineffective or inappropriate.

Mild to moderate hypotension and peripheral vasodilation may occur immediately following administration of the drug. Fluids and other countermeasures to manage hypotension should be readily available. Vital signs should be monitored routinely.

In patients with pheochromocytoma, severe hypertension and tachycardia have been observed after administration of droperidol.

As with other neuroleptic agents, rare reports of neuroleptic malignant syndrome have occurred in patients receiving droperidol.

Cases of sudden death have been reported following use of high dose droperidol. Because of these reports, droperidol is not recommended in the treatment of alcohol withdrawal or in clinical situations requiring high doses of droperidol.

Droperidol should be administered with caution to patients with liver and kidney dysfunction.

The initial dose of droperidol therapy should be appropriately reduced in elderly, debilitated and other poor-risk patients. The effect of the initial dose should be factored in determining incremental doses.

The safety of droperidol in children younger than two years of age has not been determined.

Dialysis

Data not available

Hide
(web2)